Novo Nordisk Announces Semaglutide Price Reduct...

By João L. Carapinha

February 26, 2026

Novo Nordisk Drives Semaglutide Price Reduction Novo Nordisk slashes the US semaglutide list price—or wholesale acquisition cost (WAC)—for Wegovy®, Ozempic®, and Rybelsus® to $675 per ...
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
Revised MenACWY Vaccination Strategy for Adolescents in Germany
Glofitamab Cost-Effectiveness: Conditional Reimbursement Insights for DLBCL T...
NICE Endorses Pegzilarginase for Treating Arginase Deficiency
Transformative PBM Reform Legislation Signed into Law
Disrupting Prescription Drug Pricing: Mark Cuban’s Cost-Plus Vision
Pharmaceutical Tender Investigation Sparks Regulatory Scrutiny in South Africa
South Africa Health Reform: Navigating Innovations and Challenges for 2026
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
European Pharma Competitiveness: A Cornerstone for EU Economic Resilience